MX366622B - Composicion farmaceutica estable de la proteina de fusion tnfr:fc. - Google Patents

Composicion farmaceutica estable de la proteina de fusion tnfr:fc.

Info

Publication number
MX366622B
MX366622B MX2015005231A MX2015005231A MX366622B MX 366622 B MX366622 B MX 366622B MX 2015005231 A MX2015005231 A MX 2015005231A MX 2015005231 A MX2015005231 A MX 2015005231A MX 366622 B MX366622 B MX 366622B
Authority
MX
Mexico
Prior art keywords
tnfr
fusion protein
stable pharmaceutical
pharmaceutical composition
relates
Prior art date
Application number
MX2015005231A
Other languages
English (en)
Spanish (es)
Other versions
MX2015005231A (es
Inventor
Dyaneshwar Deokar Vaibhav
Sorab Mody Rustom
Deepak Apte-Deshpande Anjali
Original Assignee
Lupin Atlantis Holdings Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lupin Atlantis Holdings Sa filed Critical Lupin Atlantis Holdings Sa
Publication of MX2015005231A publication Critical patent/MX2015005231A/es
Publication of MX366622B publication Critical patent/MX366622B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Inorganic Chemistry (AREA)
MX2015005231A 2012-10-26 2013-10-24 Composicion farmaceutica estable de la proteina de fusion tnfr:fc. MX366622B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN1235KO2012 2012-10-26
IN1236KO2012 2012-10-26
PCT/IB2013/059612 WO2014064637A1 (en) 2012-10-26 2013-10-24 Stable pharmaceutical composition of tnfr:fc fusion protein

Publications (2)

Publication Number Publication Date
MX2015005231A MX2015005231A (es) 2015-10-29
MX366622B true MX366622B (es) 2019-07-16

Family

ID=54208810

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015005231A MX366622B (es) 2012-10-26 2013-10-24 Composicion farmaceutica estable de la proteina de fusion tnfr:fc.

Country Status (14)

Country Link
US (2) US10058589B2 (enExample)
EP (1) EP2919801B1 (enExample)
JP (1) JP6431844B2 (enExample)
KR (1) KR102132050B1 (enExample)
CN (1) CN104936607A (enExample)
AU (1) AU2013336279B2 (enExample)
BR (1) BR112015009462A2 (enExample)
CA (1) CA2889271A1 (enExample)
ES (1) ES2806946T3 (enExample)
MX (1) MX366622B (enExample)
PL (1) PL2919801T3 (enExample)
PT (1) PT2919801T (enExample)
RU (1) RU2664691C2 (enExample)
WO (1) WO2014064637A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008543839A (ja) 2005-06-14 2008-12-04 アムジェン インコーポレーテッド 自己緩衝タンパク質製剤
HK1221163A1 (zh) * 2013-05-02 2017-05-26 Mabxience, S.A. Tnfr:fc融合多肽的替代配方
JP6480154B2 (ja) * 2014-11-06 2019-03-06 持田製薬株式会社 エタネルセプトの凍結乾燥製剤
MX389818B (es) * 2015-08-13 2025-03-20 Landsteiner Scient S A De C V Composicion de estabilidad mejorada de etanercept.
ES2962373T3 (es) * 2016-04-13 2024-03-18 Medimmune Llc Uso de aminoácidos como compuestos estabilizadores en composiciones farmacéuticas que contienen altas concentraciones de agentes terapéuticos basados en proteínas
ES3064802T3 (en) * 2016-10-21 2026-04-29 Amgen Inc Pharmaceutical formulations and methods of making the same
CN111432880A (zh) * 2017-08-08 2020-07-17 瑞士杰特贝林生物制品有限公司 血色素结合蛋白制剂
CA3042126A1 (en) 2018-05-03 2019-11-03 Seattle Children's Hospital (dba Seattle Children's Research Institute) Methods of treating kawasaki disease
WO2022264097A1 (en) 2021-06-17 2022-12-22 Lupin Limited Pharmaceutical composition of anti-tumour necrosis factor (anti-tnf) agent for management of infectious diseases caused by coronaviruses
CN122459015A (zh) * 2024-05-31 2026-07-24 荣昌生物制药(烟台)股份有限公司 环糊精及其衍生物作为保护剂在制备TACI-Fc融合蛋白液体药物制剂中的用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5215743A (en) 1988-04-13 1993-06-01 Maninder Singh Tumor necrosis factor formulations
US5997856A (en) * 1988-10-05 1999-12-07 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
DE4239877C1 (de) * 1992-11-27 1994-03-17 Boehringer Ingelheim Int Stabilisierte Superoxid-Dismutase (SOD)-Zusammensetzung
DK1017413T4 (da) * 1997-09-23 2008-03-25 Rentschler Biotech Gmbh Flydende formulering af interferon-beta
CA2476934C (en) * 2002-02-27 2009-06-16 Immunex Corporation Stabilized tnfr-fc composition comprising arginine
US20040033228A1 (en) * 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
EA009079B1 (ru) 2003-02-28 2007-10-26 Арес Трейдинг С.А. Жидкие составы фактор некроза опухоли-связывающих белков
ES2310122B1 (es) * 2007-04-20 2009-10-30 Instituto Cientifico Y Tecnologico De Navarra, S.A Nanoparticulas que comprenden una ciclodextrina y una molecula biologicamente activa y sus aplicaciones.
WO2009133529A2 (en) * 2008-04-30 2009-11-05 Wockhardt Research Centre Processes for refolding of insulin
US20100278822A1 (en) * 2009-05-04 2010-11-04 Abbott Biotechnology, Ltd. Stable high protein concentration formulations of human anti-tnf-alpha-antibodies
RU2600847C2 (ru) 2010-05-10 2016-10-27 Интас Биофармасьютикалс Лимитед Жидкий состав полипептидов, содержащих fc-домен иммуноглобулина
TWI603739B (zh) * 2010-11-11 2017-11-01 艾伯維生物技術有限責任公司 具有增進高濃度之抗－ＴＮＦα抗體之液體調配物
RU2614257C2 (ru) * 2011-04-20 2017-03-24 Сандоз Аг СТАБИЛЬНЫЕ ЖИДКИЕ ФАРМАЦЕВТИЧЕСКИЕ ПРЕПАРАТЫ СЛИТОГО БЕЛКА TNFR:Fc

Also Published As

Publication number Publication date
AU2013336279A1 (en) 2015-05-14
KR20150074069A (ko) 2015-07-01
CN104936607A (zh) 2015-09-23
EP2919801B1 (en) 2020-04-29
RU2664691C2 (ru) 2018-08-21
MX2015005231A (es) 2015-10-29
ES2806946T3 (es) 2021-02-19
BR112015009462A2 (pt) 2017-07-04
US20150283241A1 (en) 2015-10-08
PL2919801T3 (pl) 2021-01-25
KR102132050B1 (ko) 2020-07-10
AU2013336279B2 (en) 2018-07-19
JP2015535237A (ja) 2015-12-10
PT2919801T (pt) 2020-07-30
JP6431844B2 (ja) 2018-11-28
RU2015119603A (ru) 2016-12-20
US20180236030A1 (en) 2018-08-23
EP2919801A1 (en) 2015-09-23
US10058589B2 (en) 2018-08-28
WO2014064637A1 (en) 2014-05-01
CA2889271A1 (en) 2014-05-01

Similar Documents

Publication Publication Date Title
MX2015005231A (es) Composicion farmaceutica estable de la proteina de fusion tnfr:fc.
MX2013008702A (es) Composiciones que contienen anticuerpos glicosilados y sus usos.
WO2014039903A3 (en) Stable aqueous formulations of adalimumab
NZ703546A (en) Composition comprising a mixture of cd95-fc isoforms
MY168757A (en) Novel compounds as modulators of protein kinases
MX2014004725A (es) Formulaciones de etanercept estabilizadas con aminoacidos.
MX336682B (es) Anticuerpos contra csf-1r humanos y usos de los mismos.
MY170720A (en) Antibody formulations
MX356337B (es) Anticuerpos contra csf-1r humano y sus usos.
MY193249A (en) Anti-human cd19 antibodies with high affinity
EP4036240A3 (en) Transduction buffer
WO2014074532A3 (en) Compositions and methods for modulating cell signaling
HK1197071A1 (en) Antibodies against epidermal growth factor receptor (egfr) and uses thereof
PH12015502125A1 (en) Il-22 polypeptides and il-22 fc fusion proteins and methods of use
MY162737A (en) 4-1bb binding molecules
MX2015008446A (es) Composiciones de proteinas de union multivalentes.
MX2013002048A (es) Conjugados, particulas, composiciones y metodos relacionados.
MX363533B (es) Proteínas de fusión que comprenden partes de unión a pdgf y vegf y métodos de uso de las mismas.
WO2012135805A3 (en) Delivery and formulation of engineered nucleic acids
EP3626253A3 (en) Stable formulations of linaclotide
MX2014013149A (es) Anticuerpos anti-il-23p19.
PH12013500500A1 (en) Fused heteroaryls and their uses
MX2013000958A (es) Fabricación del inhibidor-inter-alfa (iaip) a partir de plasma.
PH12014501970A1 (en) Antibodies to bradykinin b1 receptor ligands
EP4414376A3 (en) Novel depsipeptide and uses thereof

Legal Events

Date Code Title Description
FG Grant or registration